{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:51:28Z","timestamp":1782478288644,"version":"3.54.5"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antipsychotic-induced metabolic syndrome complicates the clinical management of schizophrenia. This investigation seeks to examine berberine\u2019s efficacy and safety as adjunctive therapy in schizophrenia patients with metabolic syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A thorough literature search was executed across international (PubMed, Cochrane Library, EMBASE) and Chinese (China National Knowledge Infrastructure, WanFang Data) databases to retrieve randomized controlled trials (RCTs) examining adjunctive berberine for schizophrenia with metabolic syndrome. Data extraction and synthesis were conducted by three independent reviewers employing RevMan 5.3 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Three eligible RCTs (n = 233) were incorporated. Adjunctive berberine demonstrated superior efficacy over controls in reducing body weight (standardized mean difference (SMD) = \u22120.56, I\u00b2 = 0%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.0003), body mass index (SMD = \u22120.51, I\u00b2 = 0%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.0001), waist circumference (SMD = \u22120.31, I\u00b2 = 20%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.04), total cholesterol (mean difference (MD) = \u22120.43, I\u00b2 = 63%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.004), triglycerides (MD = \u22120.31, I\u00b2 = 0%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.0001), and fasting plasma glucose (MD = \u22120.30, I\u00b2 = 0%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.005). No significant differences existed in low density lipoprotein cholesterol (MD = -0.27, I\u00b2 = 75%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.1), high density lipoprotein cholesterol (MD = -0.02, I\u00b2 = 31%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.56), glycated hemoglobin (MD = -0.22, I\u00b2 = 67%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.21), systolic blood pressure (MD = -1.62, I\u00b2 = 0%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.17), or diastolic blood pressure (MD = -1.68, I\u00b2 = 39%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.15).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This systematic review provides preliminary evidence supporting adjunctive berberine as a promising intervention for improving certain metabolic parameters in schizophrenia patients with metabolic syndrome. Larger, high-quality RCTs are needed to confirm these observations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1846995","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T10:34:07Z","timestamp":1782297247000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjunctive berberine for schizophrenia with metabolic syndrome: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Kankan","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Beijing Chaoyang Third Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhong","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Chongqing Eleventh People\u2019s Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Chongqing Jiangbei Second Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Chongqing Eleventh People\u2019s Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yining People\u2019s Hospital","place":["Yining, Xinjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, The Affiliated Brain Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weigang","family":"Pan","sequence":"additional","affiliation":[{"name":"Peking University Huilongguan Clinical Medical School, Beijing Huilongguan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e31824d5288","article-title":"Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies","volume":"35","author":"Bou Khalil","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1089\/met.2023.0003","article-title":"Antipsychotic-induced metabolic syndrome: a review","volume":"21","author":"Akinola","year":"2023","journal-title":"Metab Syndr Relat Disord"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.47102\/annals-acadmedsg.v41n10p457","article-title":"Prevalence of metabolic syndrome among patients with schizophrenia in Singapore","volume":"41","author":"Lee","year":"2012","journal-title":"Ann Acad Med Singap"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.31083\/ap39896","article-title":"Biological susceptibility of patients with schizophrenia to metabolic syndrome: a review","volume":"26","author":"Ma","year":"2025","journal-title":"Alpha Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.31083\/ap49352","article-title":"Integrative bioinformatics analysis reveals pathogenesis biomarkers for clozapine-induced metabolic syndrome","volume":"26","author":"Wang","year":"2025","journal-title":"Alpha Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s10935-024-00798-8","article-title":"Global prevalence of metabolic syndrome in schizophrenia patients: a systematic review and meta-analysis","volume":"45","author":"Salari","year":"2024","journal-title":"J Prev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0024-3205(02)01646-6","article-title":"Physical consequences of schizophrenia and its treatment: the metabolic syndrome","volume":"71","author":"Ryan","year":"2002","journal-title":"Life Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"15s","DOI":"10.1016\/j.amjmed.2005.01.046","article-title":"Metabolic issues and cardiovascular disease in patients with psychiatric disorders","volume":"118","author":"Casey","year":"2005","journal-title":"Am J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-010-0112-8","article-title":"Metabolic syndrome associated with schizophrenia and atypical antipsychotics","volume":"10","author":"Hasnain","year":"2010","journal-title":"Curr Diabetes Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2025.13479","article-title":"Metabolic syndrome in patients with schizophrenia: underlying mechanisms and therapeutic approaches (review)","volume":"31","author":"Manta","year":"2025","journal-title":"Mol Med Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22r14490","article-title":"Comparative effects of 11 antipsychotics on weight gain and metabolic function in patients with acute schizophrenia: a dose-response meta-analysis","volume":"84","author":"Sab\u00e9","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbae173","article-title":"The optimal dosage and duration of metformin for prevention and treatment of antipsychotic-induced weight gain: an updated systematic review and meta-analysis","volume":"51","author":"Peng","year":"2025","journal-title":"Schizophr Bull"},{"key":"B13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12888-016-1049-5","article-title":"Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis","volume":"16","author":"de Silva","year":"2016","journal-title":"BMC Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","article-title":"Metabolic syndrome in people with schizophrenia: a review","volume":"8","author":"Deh","year":"2009","journal-title":"World Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/ceor.S149519","article-title":"Claims-based proxies of patient instability among commercially insured adults with schizophrenia","volume":"10","author":"Ruetsch","year":"2018","journal-title":"Clinicoecon Outcomes Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1006-7884.2020.01.002","article-title":"Chinese expert consensus on the management of metabolic syndrome in patients with schizophrenia (In Chinese)","volume":"53","year":"2020","journal-title":"Chin. J. Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbae205","article-title":"Metformin for the prevention of antipsychotic-induced weight gain: guideline development and consensus validation","volume":"51","author":"Carolan","year":"2025","journal-title":"Schizophr. Bull"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116645254","article-title":"BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment","volume":"30","author":"Cooper","year":"2016","journal-title":"J. Psychopharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2020.1822164","article-title":"Time course and dose effect of metformin on weight in patients with different disease states","volume":"13","author":"Chen","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/20451253231165169","article-title":"Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series","volume":"13","author":"Prasad","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-243938","article-title":"Rapid-onset clozapine-induced hyperglycaemia: pathways of glycaemic dysregulation","volume":"14","author":"Barbosa","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.10.014","article-title":"Metformin-associated lactic acidosis: current perspectives on causes and risk","volume":"65","author":"DeFronzo","year":"2016","journal-title":"Metabolism"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.6252","article-title":"Berberine and barberry (Berberis vulgaris): a clinical review","volume":"33","author":"Imenshahidi","year":"2019","journal-title":"Phytother Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s43440-021-00348-7","article-title":"Berberine and its derivatives represent as the promising therapeutic agents for inflammatory disorders","volume":"74","author":"Lu","year":"2022","journal-title":"Pharmacol Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2074610","article-title":"The effect of berberine on metabolic profiles in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials","volume":"2021","author":"Guo","year":"2021","journal-title":"Oxid Med Cell Longev"},{"key":"B26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1507\/endocrj.EJ18-0109","article-title":"Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis","volume":"66","author":"Liang","year":"2019","journal-title":"Endocr J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-022-00976-2","article-title":"The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta-analysis of randomized controlled trials","volume":"30","author":"Lu","year":"2022","journal-title":"Inflammopharmacology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2020.102337","article-title":"Effects of berberine and barberry on anthropometric measures: a systematic review and meta-analysis of randomized controlled trials","volume":"49","author":"Amini","year":"2020","journal-title":"Complement Ther Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jep.2014.09.049","article-title":"Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension","volume":"161","author":"Lan","year":"2015","journal-title":"J Ethnopharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1142\/s0192415x21500920","article-title":"Effects of berberine on gut microbiota in patients with mild metabolic disorders induced by olanzapine","volume":"49","author":"Pu","year":"2021","journal-title":"Am J Chin Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2021.102896","article-title":"Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin","volume":"67","author":"Qiu","year":"2022","journal-title":"Asian J Psychiatr"},{"key":"B32","article-title":"Clinical study of berberine in the treatment of metabolic syndrome in patients with schizophrenia (In Chinese)","volume":"29","author":"Li","year":"2016","journal-title":"Sichuan Ment Health."},{"key":"B33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/pcn.13323","article-title":"Adjunctive berberine reduces antipsychotic\u2010associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial","volume":"76","author":"Chan","year":"2022","journal-title":"Psychiatry Clin Neurosci"},{"key":"B34","article-title":"Efficacy study of berberine in the treatment of schizophrenia complicated with metabolic syndrome (In Chinese)","volume":"27","author":"Mei","year":"2016","journal-title":"Chin J Matern Child Health Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.16424\/j.cnki.cn32-1807\/r.2023.06.002","article-title":"Clinical study of berberine in the treatment of metabolic syndrome in patients with schizophrenia (In Chinese)","volume":"43","author":"Zhang","year":"2023","journal-title":"J Nantong Univ (Med Sci)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.phymed.2018.09.212","article-title":"Efficacy and safety of berberine for dyslipidaemias: a systematic review and meta-analysis of randomized clinical trials","volume":"50","author":"Ju","year":"2018","journal-title":"Phytomedicine"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjnut.2023.08.016","article-title":"Overall and sex-specific effect of berberine on glycemic and insulin-related traits: a systematic review and meta-analysis of randomized controlled trials","volume":"153","author":"Zhao","year":"2023","journal-title":"J Nutr"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome--a new world-wide definition. a consensus statement from the International Diabetes Federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabetes Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"292","DOI":"10.19538\/j.nk2018040108","article-title":"Guidelines for the prevention and treatment of type 2 diabetes in China (2017 edition) (In Chinese)","volume":"38","year":"2018","journal-title":"Chin J Pract Intern Med"},{"key":"B41","volume-title":"Clinical study of berberine in the treatment of metabolic syndrome in patients with schizophrenia","author":"Zhang","year":"2020"},{"key":"B42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13020-023-00746-4","article-title":"Berberine improves negative symptoms and cognitive function in patients with chronic schizophrenia via anti-inflammatory effect: a randomized clinical trial","volume":"18","author":"Pu","year":"2023","journal-title":"Chin Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.113899","article-title":"The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial","volume":"300","author":"Li","year":"2021","journal-title":"Psychiatry Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.18502\/ijps.v18i3.13015","article-title":"Evaluation of the effect of barberry root (Berberis vulgaris) on the prevention of metabolic syndrome caused by atypical antipsychotic drugs in patients with schizophrenia: a three-blind placebo-controlled clinical trial","volume":"18","author":"Rostami","year":"2023","journal-title":"Iran J Psychiatry"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-021-01359-4","article-title":"Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia","volume":"272","author":"Li","year":"2022","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"B46","volume-title":"Study on berberine improving metabolic and cognitive dysfunction in chronic schizophrenia patients taking olanzapine","author":"Ni","year":"2024"},{"key":"B47","volume-title":"Effects of metformin and berberine on glucose and lipid metabolism disorders induced by antipsychotics","author":"Fan","year":"2024"},{"key":"B48","article-title":"Early intervention of berberine on glucose and lipid metabolism disorders in schizophrenia patients induced by olanzapine (In Chinese)","volume":"46","author":"Feng","year":"2023","journal-title":"J Jining Med Univ"},{"key":"B49","article-title":"Efficacy of berberine in the treatment of insulin resistance induced by olanzapine in schizophrenia patients and its effect on inflammatory factor-related proteins (In Chinese)","volume":"36","author":"Mu","year":"2024","journal-title":"Mod Pract Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.20135\/j.issn.1006-8147.2018.02.016","article-title":"Effects of berberine hydrochloride on lipid metabolism and C-reactive protein in patients with schizophrenia (In Chinese)","volume":"24","author":"Ma","year":"2018","journal-title":"J Tianjin Med Univ"},{"key":"B51","volume-title":"A controlled study of berberine and lifestyle intervention in the treatment of metabolic syndrome in patients with schizophrenia","author":"Li","year":"2016"},{"key":"B52","volume-title":"A comparative study on the efficacy and safety of berberine and metformin in the treatment of schizophrenia complicated with metabolic syndrome","author":"Li","year":"2017"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.13479\/j.cnki.jip.2019.01.028","article-title":"Effects of berberine hydrochloride and metformin on regulating lipid metabolism in schizophrenia patients with metabolic syndrome (In Chinese)","volume":"46","author":"Zhao","year":"2019","journal-title":"J Int Psychiatr"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clin Trials"},{"key":"B56","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2022"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1572197","article-title":"Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"16","author":"Liu","year":"2025","journal-title":"Front Pharmacol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctcp.2020.101113","article-title":"The effect of berberine supplementation on obesity indices: A dose- response meta-analysis and systematic review of randomized controlled trials","volume":"39","author":"Xiong","year":"2020","journal-title":"Complement Ther Clin Pract"},{"key":"B61","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2147\/dmso.S181572","article-title":"Barberry in the treatment of obesity and metabolic syndrome: possible mechanisms of action","volume":"11","author":"Firouzi","year":"2018","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27041351","article-title":"Berberine, a herbal metabolite in the metabolic syndrome: the risk factors, course, and consequences of the disease","volume":"27","author":"Och","year":"2022","journal-title":"Molecules"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.fitote.2009.10.010","article-title":"Berberine inhibits adipogenesis in high-fat diet-induced obesity mice","volume":"81","author":"Hu","year":"2010","journal-title":"Fitoterapia"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-024-2834-8","article-title":"Berberine dissociates mitochondrial complex I by SIRT3-dependent deacetylation of NDUFS1 to improve hepatocellular glucose and lipid metabolism","volume":"68","author":"Wang","year":"2025","journal-title":"Sci China Life Sci"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.54604","article-title":"Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver","volume":"17","author":"Yu","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00647","article-title":"Berberine improves glucose and lipid metabolism in HepG2 cells through AMPK\u03b11 activation","volume":"11","author":"Ren","year":"2020","journal-title":"Front Pharmacol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/ph18121890","article-title":"Berberine: a rising star in the management of type 2 diabetes-novel insights into its anti-inflammatory, metabolic, and epigenetic mechanisms","volume":"18","author":"Liu","year":"2025","journal-title":"Pharm (Basel)"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.278","article-title":"Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization","volume":"7","author":"Howes","year":"2017","journal-title":"Transl Psychiatry"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2006.07.011","article-title":"Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia","volume":"149","author":"Fan","year":"2007","journal-title":"Psychiatry Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2012.12010109","article-title":"The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation","volume":"170","author":"Kring","year":"2013","journal-title":"Am J Psychiatry"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbq059","article-title":"The brief negative symptom scale: psychometric properties","volume":"37","author":"Kirkpatrick","year":"2011","journal-title":"Schizophr Bull"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)02365-7","article-title":"Comparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases","volume":"407","author":"Schneider-Thoma","year":"2026","journal-title":"Lancet"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1846995\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:39:12Z","timestamp":1782477552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1846995\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":72,"alternative-id":["10.3389\/fpsyt.2026.1846995"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1846995","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"article-number":"1846995"}}